anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Research on circulating tumor cells (CTCs) offers the opportunity to better understand the initial steps of blood-borne metastasis as main cause of cancer-related deaths. Here, we have used the colon cancer CTC-MCC-41 and breast cancer CTC-ITB-01 lines, which were both established from human CTCs as permanent cell lines as models to further study CTC biology with special emphasis on anchorage-independent survival and growth.
METHODS AND RESULTS: Both cell lines showed a marked intrinsic plasticity to switch between suspension and adherent in vitro growth, in 2D adherent culture conditions, and established an equilibrium of both growth patterns with predominant adherent cells in the CTC-MCC-41 line (77%) and suspension cells in the CTC-ITB-01 line (85%). Western blot analysis revealed a higher expression of pERK1/2 in CTC-ITB-01 adherent cells compared to the suspension counterpart that suggested the involvement of kinases in this process. Subsequent functional kinome profiling identified several serine/threonine as well as tyrosine kinases that were differentially regulated in adherent and suspension CTCs. In the adherent cells of the breast cancer line CTC-ITB-01 the activity of MSK1, Src family kinases and the PKG family was increased compared to the suspension counterpart. In adherent cells of the colorectal CTC-MCC-41 line, an increased activity of TYRO3 and JAK2 was detected, whereas p38 MAPK was strongly impaired in the suspension CTC-MCC-41 cells. Some of the regulated kinases, which include the Src family, TYRO3, MSK1, JAK2 and p38 MAPK, have been associated with crucial cellular processes including proliferation, migration and dormancy in the past.
CONCLUSIONS: The investigated CTC lines exhibit a high plasticity, similar to the concept of 'adherent-to-suspension transition (AST)' that was recently suggested as a new hallmark of tumor biology by Huh et al. Moreover, we identified differentially regulated kinome profiles that may represent potential targets for future studies on therapeutic interventions.
The invention discloses a child medicament extract composition, which has the effects of clearing away heat, relieving cough, resisting inflammation and relieving pain. Compared with the conventional child medicament particle, a novel preparation disclosed by the invention has the advantages of reduction in the specific surface area, higher damp proofing and light shading performance and great improvement on the stability of active ingredients. Moreover, the child medicament extract composition is more suitable for children, effervesces and and is dissolved quickly in water, is convenient to carry, and is rapid for taking. The conventional child medicament particle is an ordinary particle with poor dissolvability, has certain irritant smell since calculus bovis factitious and volatile oil are directly added in a prescription, and is very instable. A child medicament extract effervescent tablet disclosed by the invention effervesces and is dissolved quickly in water; after calculus bovis factitious and volatile oil are included by beta-cyclodextrin, irritant smell is avoided, and medicament stability is enhanced; and the process and quality of a product are controllable, safe and effective. A child medicament capsule disclosed by the invention is more suitable for adults; a capsule shell is damp-proof and light-resistant, so that the stability of calculus bovis factitious is enhanced greatly; and meanwhile, irritant smell is avoided simultaneously.
The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
PURPOSE:To establish a diagnostic method using a cancer marker produced specifically in a cancerous cell, by making an anti-cathepsin E antibody or an anti-procathepsin E antibody react with a sample and by detecting a conjugated body of cathepsin E or procathepsin E in the sample and the antibody. CONSTITUTION:A diagnosis of cancer is executed by making an anti-cathepsin E antibody or an anti-procathepsin E antibody react with a sample and by detecting a conjugated body of cathepsin E or procathepsin E in the sample and the antibody. The cathepsin can be detected by making the antibody thereof react therewith and by detecting the conjugated body being a reaction product. As for the sample, a tissue slice of each sort of internal organ or a liquid constituent of an organism such as a serum or urine is used. In the case when the tissue slice is used as the sample, the tissue slice is subjected to immunological dyeing by using the anti-cathepsin E antibody and the presence or absence of revelation of the cathepsin E is observed. When the sample is the liquid constituent of the organism, the anti-cathepsin E antibody is used and the cathepsin E is detected by a measuring method such as a sandwich method or a competing method, for instance.
The invention provides methods, apparatus and kits for regenerating dental tissue in vivo that are useful for treating a variety of dental conditions, exemplified by treatment of caries. The invention uses tissue scaffold wafers, preferably made of PGA, PLLA, PDLLA or PLGA dimensioned to fit into a hole of corresponding sized drilled into the tooth of subject to expose dental pulp in vivo. In certain embodiments the tissue scaffold wafer further comprises calcium phosphate and fluoride. The tissue scaffold wafer may be secured into the hole with a hydrogel, a cement or other suitable material. Either the wafer or the hydrogel or both contain a morphogenic agent, such as a member encoded by the TGF-β supergene family, that promotes regeneration and differentiation of healthy dental tissue in vivo, which in turn leads to remineralization of dentin and enamel. The tissue scaffold may further include an antibiotic or anti-inflammatory agent.
In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Hepatitis C treatment will include Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg administered on-call to the operating room for the renal transplant procedure and continued for 12 weeks post-renal transplant. The donor hepatitis C genotype will be tested. If the donor has genotype 1a without resistance or genotype 1b treatment will remain GZR/EBR for 12 weeks. If the donor has genotype 1a with resistance variants, then Ribavirin will be added and treatment will be given for 16 weeks starting from the date ribavirin was added. If the donor has hepatitis C genotype 2 or 3, Sofosbuvir will be added and treatment will be for 12 weeks from the date Sofosbuvir was added.
BACKGROUND & AIMS: In patients with cirrhosis, continued heavy alcohol consumption and obesity may increase risk of hepatocellular carcinoma (HCC). We examined whether germline susceptibility to hepatic steatosis not only independently predisposes to HCC but may also act synergistically with other risk factors.
METHODS: We analyzed data from 1911 patients in 2 multicenter prospective cohort studies in the United States. We classified patients according to alcohol consumption (current heavy vs not current heavy), obesity (body mass index ≥30 vs <30 kg/m2), and PNPLA3 I148M variant status (carrier of at least one G risk allele vs noncarrier). We examined the independent and joint effects of these risk factors on risk of developing HCC using Cox regression with competing risks.
RESULTS: Mean age was 59.6 years, 64.3% were male, 28.7% were Hispanic, 18.3% were non-Hispanic Black, 50.9% were obese, 6.2% had current heavy alcohol consumption, and 58.4% harbored at least 1 PNPLA3 G-allele. One hundred sixteen patients developed HCC. Compared with PNPLA3 noncarriers without heavy alcohol consumption, HCC risk was 2.65-fold higher (hazard ratio [HR], 2.65; 95% confidence interval [CI], 1.20-5.86) for carriers who had current heavy alcohol consumption. Compared with noncarrier patients without obesity, HCC risk was higher (HR, 2.40; 95% CI, 1.33-4.31) for carrier patients who were obese. PNPLA3 and alcohol consumption effect was stronger among patients with viral etiology of cirrhosis (HR, 3.42; 95% CI, 1.31-8.90). PNPLA3 improved 1-year risk prediction for HCC when added to a clinical risk model.
CONCLUSIONS: The PNPLA3 variant may help refine risk stratification for HCC in patients with cirrhosis with heavy alcohol consumption or obesity who may need specific preventive measures.
FIELD: chemistry. ^ SUBSTANCE: invention relates to immunology and biotechnology. Described are versions of the humanised antibody CD45RO/RB which carry a light and a heavy strand. Versions of the following are disclosed: isolated polynucleotide, coding antibody, expression vector containing a polynucleotide and host cells containing the expression vector. Described also is use of the antibody to treat and/or prevent various diseases, including as a component of a pharmaceutical composition. ^ EFFECT: invention provides antibodies identified as CD45RO and CD45RB, which can find use in medicine. ^ 9 cl, 14 dwg, 2 tbl, 13 ex
OBJECTIVE: In this study, we explored the neuroprotective effect of melittin (MEL) after brain ischemia using a rat model.
METHODS: The rats underwent middle cerebral artery occlusion (MCAO) for 60 min and were randomly divided into the control group, saline group, and MEL group. Rats in each group were injected intraperitoneally with MEL one day before MCAO until sacrificed. Morris water maze and rotation test were used to assess locomotor function and cognitive ability. The 9.4 Tesla MRI was used to scan and assess the infarct volume of the rat brains. Immunohistochemistry was used to detect the sites of action of MEL on microglia. Western blot and ELISA were used to measure the effect of MEL on the production of pro-inflammatory cytokines. The effect of MEL on neuronal cell apoptosis was observed by flow cytometry.
RESULTS: Compared with the saline group, MEL treatment significantly increased the density of neurons in the cerebral cortical and reduced the cerebral infarct size after MCAO (33.9 ± 8.8% vs. 15.8 ± 3.9%, P < 0.05). Meanwhile, the time for MEL-treated rats to complete the water maze task on the 11th day after MCAO was significantly shorter than that of rats in the saline group (P < 0.05). MEL treatment also prolonged the rotarod retention time on day 14 after MCAO. Immunohistochemistry analysis showed that MEL inhibited the activation of microglia and suppressed the expression of TNF-α, IL-6, and IL-1β in the brain after ischemia. MEL treatment resulted in a significant decrease in TLR4, MyD88, and NF-κB p65 levels in extracts from the ischemic cerebral cortex. Finally, MEL reduced neuronal apoptosis induced by ischemic stroke (P < 0.05).
CONCLUSION: MEL treatment promotes neurological function recovery after cerebral ischemia in rats. These effects are potentially mediated through anti-inflammatory and anti-apoptotic mechanisms.
Sarcopenia, the progressive decline of muscle mass and function, has traditionally been viewed as an age-related process leading to a broad range of adverse outcomes. However, it has been widely reported that sarcopenia can occur earlier in life in association with various conditions (i.e. disease-related sarcopenia), including neuromuscular disorders. As early as 2010, the European Working Group on Sarcopenia in Older People included neurodegenerative diseases characterised by motor neuron loss among the mechanisms underlying sarcopenia. Despite some differences in pathogenetic mechanisms, both amyotrophic lateral sclerosis (ALS) and age-related sarcopenia share common characteristics, such as the loss of motor units and muscle fibre atrophy, oxidative stress, mitochondrial dysfunction and inflammation. The histology of older muscle shows fibre size heterogeneity, fibre grouping and a loss of satellite cells, similar to what is observed in ALS patients. Regrettably, the sarcopenic process in ALS patients has been largely overlooked, and literature on the condition in this patient group is very scarce. Some instruments used for the assessment of sarcopenia in older people could also be applied to ALS patients. At this time, there is no approved specific pharmacological treatment to reverse damage to motor neurons or cure ALS, just as there is none for sarcopenia. However, some agents targeting the muscle, like myostatin and mammalian target of rapamycin inhibitors, are under investigation both in the sarcopenia and ALS context. The development of new therapeutic agents targeting the skeletal muscle may indeed be beneficial to both ALS patients and older people with sarcopenia.
When a participant has persistent or recurrent IDA (defined as hemoglobin \<12.0 grams \[g\]/deciliter \[dL\] and with either transferrin saturation \<40% or ferritin \<100 nanograms/milliliter), the participant will begin a 7-week treatment period. Participants will receive 2 IV injections of ferumoxytol 7.0 milligrams (mg) iron/kilogram (maximum of 510 mg/dose), the first dose administered on Day 1 and the second on Days 3 through 9 of the Treatment Period.
The invention relates to mandarin orange and arabian jasmine flower rice wine which is prepared from the following raw materials in parts by weight: 300-320 parts of sticky rice, 50-60 parts of maize, 4-5 parts of distiller's yeasts, 50-60 parts of mandarin oranges, 30-40 parts of tender niblets, 30-40 parts of pineapple vinegar, 10-12 parts of arabian jasmine flowers, 3-5 parts of scorched hawthorn fruits, 4-6 parts of liquorice, 3-5 parts of roots of chinese pulsatilla and the like. The invention discloses the mandarin orange and arabian jasmine flower rice wine and a preparation process thereof. In the preparation process, pure natural materials are adopted without adding any preservatives. The mandarin oranges and tender niblets are added, so that the rice wine is sour and sweet in taste and abundant in nutrition. Extracts of the arabian jasmine flowers, the scorched hawthorn fruits, the liquorice, the roots of chinese pulsatilla and the like are added, so that the rice wine has a good effect of removing food retention and appetizing, warming the middle warmer and harmonizing stomach and the like. The rice wine is particularly suitable for people with stomach discomfort.
The invention discloses an external Miao medicine for treating osteoproliferation. The external Miao medicine is prepared from 15-20 parts by mass of root of bidentate achyranthes, 20-25 parts by mass of Schisandra rubriflora(Franch.)Rehd.etWils., 20-25 parts by mass of honeysuckle stem, 15-20 parts by mass of lily, 10-15 parts by mass of Chinese azalea flower, 15-20 parts by mass of frankincense, 15-20 parts by weight of myrrh and 20-25 parts by weight of radix aconiti. A preparation method of the external Miao medicine comprises respectively cleaning the above eight traditional Chinese medicines, carrying out drying by hot air, carrying out fragmentation to obtain fragments, carrying out disinfection by ultraviolet light, mixing the above materials according to the formula to obtain a uniform mixture, and carrying out crushing and grinding to obtain powder of 60 meshes. The external Miao medicine is stored in a shady and dry place and can be momentarily taken in use. In use, at every turn, 40-50g of the medical powder and liquor with alcoholic strength of 45 degrees or vinegar are blended to form paste, the paste is packaged by a white cloth or gauze to form blocks, and the blocks are pasted to osteoproliferation parts with pain. The external Miao medicine for treating osteoproliferation has effects of invigorating blood circulation and relieving pain, and strengthening tendons and dredging collaterals, has obvious curative effects and is suitable for treatment on osteoproliferation of patients.
PROBLEM TO BE SOLVED: To provide a safe and readily ingestible IgE antibody-suppressing agent or food capable of suppressing an IgE antibody value in vivo, preventing onset of allergic diseases such as atopic dermatitis, bronchitis and allergic rhinitis and improving a clinical picture even when these diseases are affected. SOLUTION: This IgE antibody-suppressing agent comprises glucomannan. Preferably the glucomannan has a shape of refined flour of devil's tongue and >=95% dietary fiber content and the glucomannan is readily water-soluble. Preferably, the glucomannan is subjected to powering treatment in order to make the glucomannan readily water-soluble. Preferably the powered glucomannan has >=1,000,000 weight average molecular weight and <=100 μm average particle diameter and a time required for 1% aqueous solution at room temperature to attain viscosity peak is within 30 min. The IgE antibody-suppressing agent has a form of powder, capsule, tablet, pill or granule.
The SAVE system aims to offer technology-based support to older adults for staying in their familiar surroundings for as long as possible, while feeling safe and optimally cared for. The SAVE technology has been designed and developed according to the approach of the User Centered Design (UCD), which involves multiple interactions with users to under-stand their needs and preferences and to involve them in the design process for creating a truly useful and appreciated technological product. Secondarily, it supports informal caregivers, like relatives, in providing optimal care for their loved ones, while maintaining their professional and private life. The general objective of this study is to test the usability and efficiency of the SAVE prototype for enabling older adults to keep their independent and active lives in their homes and maintain their social relationships for as long as possible. The study involves the use of the SAVE platform for a total of 21 consecutive days.The study involves the use of a mixed-methods approach, in which both qualitative (open questions) and quantitative (standardized tests) data will be collected, and three different measurements (T0, T1, T2) will be made during the period of use of the system. The data collection card will therefore be divided into two different sections, which correspond to the three different moments of detection: 1) at time 0, that is, before the start of the experi-mentation (T0); 2) at time 1, after 10 days, i.e. at the midterm of the trial (T1), and 3) at time 2, after 21 days, i.e., at the end of the trial (T2). The log data of the usage of the SAVE sys-tem be the primary, secondary, and tertiary users will be continuously stored over the 21 days test period.
Thirty to fifty percent of individuals with HIV can be expected to have diarrhea at some point during their illness. Diarrhea can be a chronic condition in HIV disease wherein three or more daily episodes of loose, watery stools are experienced for 4 weeks or more. Chronic diarrhea has been associated with significant morbidity, weight loss, and severe malnutrition. Researchers have reported that patients with chronic diarrhea experience a marked decrease in quality of life in comparison with HIV patients without diarrhea.

The goal of nutrition management for patients with chronic diarrhea is to ensure that adequate caloric consumption meets the metabolic needs of such individuals and to provide symptomatic relief. HIV infection, regardless of stage, causes an increase in resting energy expenditure because of the response of the body to the viral infection. Proper nutrition management can therefore assist in preventing further nutritional imbalances.
The present invention relates to a traditional Chinese medicinal preparation for treating acute and chronic bronchitis and a production method thereof. The traditional Chinese medicinal preparation is prepared from ternate buttercup root, notoginseng, common bletilla pseudobulb, lily bulb, gecko, extractum of fewflower lysionotus herb and extractum of stemona root. Compared with the prior art, the present invention is developed according to the traditional proved recipe of minority regions, the medicine does not have toxic or side effect and is safe and reliable, and the effect is relatively obvious. Simultaneously, the provided production method is simple and can not result in loss of effective ingredients or influence the effect of the medicine for the production of the raw medicinal materials provided by the present invention. The medicine has the functions of nourishing yin, moistening the lung, relieving cough and eliminating phlegm. The medicine is used for the treatment of acute and chronic bronchitis, cough with dyspnea and hemoptysis, and also has the auxiliary therapeutic effect on pulmonary tuberculosis and scrofula.
This is a single center, single-blinded randomized cross over design trial, that will compare the impact of IN naloxone vs. IN saline during experimental hypoglycemia on day one on the responses to experimental hypoglycemia on day two. 18 participants will be studied twice, 8 weeks apart. On each occasion participants will undergo a 2 hour hypoglycemic clamp (target 50 mg/dl) in the morning and in the afternoon on day one and then again on the morning of day 2. During the morning clamps, samples will be collected for later measurement of serum epinephrine, glucagon and cortisol levels and participants will be asked to complete a hypoglycemia symptom questionnaire. 3 intranasal doses (4 mg each) of naloxone hydrochloride or IN saline will be administered to the subject on day 1. Plasma will be collected for measurement of naloxone concentrations on day 1 primary outcome is the difference in peak epinephrine secretion during the morning episodes of hypoglycemia on days one and two, thus each participant will have two observations: one from their naloxone experiment and one from their saline experiment.

Secondary endpoint will be naloxone pharmacokinetics including maximum concentration (Cmax), time to maximum concentration (Tmax) and area under the curve (AUC)
Based on animal studies and its mechanism of action, STIVARGA can cause fetal harm when administered to a pregnant woman. There are no available data on STIVARGA use in pregnant women. Regorafenib was embryolethal and teratogenic in rats and rabbits at exposures lower than human exposures at the recommended dose, with increased incidences of cardiovascular, genitourinary, and skeletal malformations. Advise pregnant women of the potential risk to a fetus. 

Advise females of reproductive potential to use effective contraception during treatment with STIVARGA and for 2 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with STIVARGA and for 2 months after the final dose [see Use in Specific Populations (8.1), (8.3)].
The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate.
This study is a prospective randomised double-blind placebo-controlled trial. Patients who meet the criteria for inclusion/exclusion will be evaluated. Melatonin tablets will be administered as a premedication to patients in the melatonin group. Patients in the control group will be given placebo tablets as a premedication. Fentanyl 1ug/kg and propofol 1-2 mg/kg will be used to induce anaesthesia. Atracurium 0.5 mg/kg will be used for the facilitation of endotracheal intubation. Isoflurane will be used to maintain anaesthesia and the depth of anaesthesia will be adjusted by a Bispectral index monitor. Postoperatively, the patients will be monitored for the development of delirium.